Traditional Chinese medicine effective part composition for treating chronic kidney disease and preparation method thereof
By preparing a traditional Chinese medicine composition containing astragalus polysaccharide, astragalus saponin, icariin, quercetin and rhubarb anthraquinone crude extract, the problem of lack of effective treatment of chronic kidney disease in the prior art was solved, and the problem of composition of prescriptions in the prior art was achieved. Effective treatment and kidney protection for chronic kidney disease.
Patent Information
- Application Number
- CN202411187087.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-11-12
AI Technical Summary
The existing technology lacks a clear effective Chinese medicine prescription for the treatment of chronic kidney disease and research on its mechanism of action, resulting in unclear effects of Chinese medicine intervention.
A composition of effective part of traditional Chinese medicine, including astragalus polysaccharide, astragalus saponin, icariin, quercetin and rhubarb anthraquinone crude extract, is used to prepare a dosage form suitable for clinical use through specific mass ratios and preparation methods, and use In the treatment of chronic kidney disease.
This traditional Chinese medicine composition shows good therapeutic effects, can effectively protect the residual kidneys, reduce renal fibrosis, improve clinical symptoms, and verify its safety and effectiveness through clinical studies.
Smart Images

Figure CN118924810A_ABST
Abstract
Description
Technical field:
[0001] The present invention relates to the technical field of traditional Chinese medicines, and in particular to a traditional Chinese medicine effective part composition for treating chronic kidney disease and a preparation method thereof. Background technology:
[0002] Chronic kidney disease (CKD) refers to the presence of renal damage or decreased renal function for ≥3 months, regardless of the cause. Renal damage refers to abnormal renal structure or function, with or without decreased glomerular filtration rate (GFR), manifested by one of the following: pathological abnormalities; renal damage indicators including abnormal blood or urine components, or abnormal imaging examinations; GFR <60mL / min / 1.73m2 for ≥3 months.
[0003] CKD is a group of progressive and intractable diseases that will eventually lead to end-stage renal disease (ESRD). It not only has a high mortality and disability rate, but also consumes huge amounts of health resources. According to statistics, in developed countries such as Europe and the United States, although the ESRD population only accounts for 6% of the total medical population, its consumption accounts for 24% of the total medical budget. In recent years, the number of patients with chronic renal failure (CRF) undergoing renal replacement therapy in my country has increased at a rate of 11%. The dialysis registration data in Beijing shows that the mortality rate of dialysis patients is about 10% per year. When the blood creatinine of CKD patients exceeds 150μmol / L, the number of deaths from cardiovascular complications is 15 times that of the general population. At present, the prevention and treatment of CKD in my country is still very weak, and the clinical prevention and treatment guidelines for CKD are mostly based on foreign clinical evidence, which is difficult to fully adapt to the Chinese population. Therefore, when the prevention and treatment strategy of CKD has become a global public health event, it is of great social and economic significance to actively intervene, prevent and treat CKD and delay the progression of CRF by using effective methods of combining traditional Chinese and Western medicine.
[0004] At present, intervention measures to slow down the progressive deterioration of CKD mainly focus on low-protein diet, use of ACEI / ARB drugs, lipid-lowering therapy, and control of complications. As the course of CRF in patients progresses, drug treatment is limited and the difficulty of controlling complications increases. In recent years, research on the intervention of traditional Chinese medicine in CKD has become a focus of attention. Research on the use of traditional Chinese medicine to improve renal fibrosis and delay the progression of CRF has also achieved corresponding results. The combination of traditional Chinese and Western medicine treatment methods involving traditional Chinese medicine has become an important part of my country's CKD prevention and treatment program. However, the current research on the mechanism of traditional Chinese medicine intervention in CRF needs to be deepened. There is still a lack of clear effective traditional Chinese medicine formulas for the treatment of chronic kidney disease, and there are no high-quality randomized controlled clinical studies. The therapeutic effect and mechanism of traditional Chinese medicine on chronic kidney disease need to be further clarified. Summary of the invention:
[0005] 1. Technical issues to be solved
[0006] In view of the defects of the prior art, the present invention provides a composition of effective parts of traditional Chinese medicine for treating chronic kidney disease and a preparation method thereof, extracts effective ingredients for treating chronic kidney disease from traditional Chinese medicine, and studies their optimal weight ratio, thereby solving the problems in the prior art that the mechanism of action of traditional Chinese medicine on chronic kidney disease is unclear and there is a lack of effective traditional Chinese medicine prescriptions for treating chronic kidney disease.
[0007] (II) Technical solution
[0008] In order to solve the above technical problems, the present invention adopts the following technical solutions:
[0009] A composition of effective parts of traditional Chinese medicine for treating chronic kidney disease, wherein the effective ingredients of the composition of effective parts of traditional Chinese medicine include astragalus polysaccharide, astragalus saponin, icariin, quercetin and crude extract of rhubarb anthraquinone, and the mass ratio of the astragalus polysaccharide, astragalus saponin, icariin, quercetin and crude extract of rhubarb anthraquinone in the composition of effective parts of traditional Chinese medicine is: 1-3 parts of crude extract of astragalus polysaccharide, 1-3 parts of crude extract of astragalus saponin, 1-2 parts of crude extract of icariin, 1-2 parts of crude extract of quercetin and 1-3.2 parts of crude extract of rhubarb anthraquinone.
[0010] The present invention also provides a method for preparing a composition of effective parts of traditional Chinese medicine for treating chronic kidney disease, comprising the following steps:
[0011] S1, take 1 portion of Astragalus, add 8 times the amount of water and boil twice, each time for 1 hour, filter separately, combine the two filtrates, refrigerate for 12 hours, centrifuge, take the supernatant, and use hollow fiber ultrafiltration to obtain a concentrated liquid part enriched in polysaccharides and a permeate part enriched in saponins, apply the permeate part to an AB-8 resin column, elute with 95% ethanol, recover the ethanol under reduced pressure, and obtain crude polysaccharides and saponins, dry the crude polysaccharides and saponins, and set aside;
[0012] S2, take 2 parts of epimedium, extract with 10 times the amount of 70% ethanol under reflux twice, each time for 1 hour, combine the extracts, filter, concentrate the filtrate under reduced pressure to a thick paste, dilute it 3 to 4 times with distilled water, let it stand for 2 hours, filter, obtain a crude extract of icariin, dry it, and set aside;
[0013] S3, taking 2 parts of Epimedium, reflux extracting with 6 times amount of 100% methanol twice, each time for 45 minutes, combining the extracts, filtering, concentrating the filtrate under reduced pressure to a thick paste, diluting it 3 to 4 times with distilled water, standing for 2 hours, filtering, obtaining a crude extract of quercetin, drying it, and setting it aside;
[0014] S4, take 1 portion of rhubarb, extract twice with 10 times the amount of 70% ethanol under reflux, each time for 1 hour, combine the extracts, filter, and concentrate the filtrate under reduced pressure to a thick paste, dilute it 3 to 4 times with distilled water, let it stand for 2 hours, filter, and obtain a crude anthraquinone extract of rhubarb for standby use;
[0015] S5, combining and concentrating the astragalus polysaccharide, astragaloside, icariin, quercetin and rhubarb anthraquinone crude extracts obtained in the above steps according to a component mass ratio of 1-3:1-3:1-2:1-2:1-3.2, and adding auxiliary materials to prepare a clinically applicable dosage form.
[0016] Furthermore, the dosage form includes granules, tablets, capsules or liquid preparations.
[0017] Furthermore, the granules are prepared by combining, concentrating and adding dextrin the astragaloside, astragaloside IV, icariin, quercetin and the crude extract of rhubarb anthraquinone in a composition ratio of 1.5:1.5:1.0:1.0:1.6;
[0018] Furthermore, every 10 grams of the effective part composition of the traditional Chinese medicine contains 2.5 mg of astragalus polysaccharide, not less than 2.5 mg of astragaloside IV, not less than 1.8 mg of icariin, not less than 2.8 mg of 1,8-dihydroxyanthraquinone, and not less than 1.8 mg of quercetin.
[0019] As another aspect of the present invention, also provided is the use of the above-mentioned composition of effective parts of traditional Chinese medicine in the preparation of drugs for treating chronic kidney disease.
[0020] (III) Beneficial effects
[0021] The beneficial effects produced by the present invention are:
[0022] (1) The effective part composition of traditional Chinese medicine for treating chronic kidney disease provided by the present invention is prepared by separating and extracting the effective traditional Chinese medicine components for treating chronic kidney disease, which mainly include astragalus polysaccharide, astragaloside I, icariin, quercetin, rhubarb anthraquinone, etc., and by studying the appropriate weight ratio, a pharmaceutical dosage form suitable for clinical use is developed, which has a good therapeutic effect on chronic kidney disease, has abundant drug sources, simple formula, special medicinal essence, and both attacking and supplementing effects, with complementary effects.
[0023] (2) The present invention uses the effective part composition of traditional Chinese medicine to gavage mice to observe the survival status and acute toxicity test response. By using different concentrations of the effective part composition of traditional Chinese medicine to gavage 5 / 6 nephrectomy residual kidney model rats, the protective mechanism of the effective part composition on the kidneys of residual kidney rats and its clinical efficacy are studied, in order to provide a basis for the clinical application of the effective part composition of traditional Chinese medicine.
[0024] (3) The present invention separates and extracts astragaloside, astragaloside IV, icariin, quercetin and rhubarb anthraquinone through a semi-bionic method and processes them into sugar-free granules, which provides feasibility for the production of granules and tablets. The preparation process of the preparation is simple, the quality is stable and the repeatability is good. Description of the drawings:
[0025] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below.
[0026] Figure 1 This is the result of HE staining of renal tissue in the remnant kidney rat model.
[0027] Figure 2 This is the result of Masson staining of renal tissue in the remnant kidney rat model.
[0028] Figure 3 This is the result of Col-IV immunohistochemistry in renal tissue of the remnant kidney rat model.
[0029] Figure 4 This is the result of PCNA immunohistochemistry in renal tissue of the remnant kidney rat model. Specific implementation method:
[0030] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in conjunction with specific embodiments.
[0031] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.
[0032] Example 1. Preparation of a composition of effective parts of traditional Chinese medicine for treating chronic kidney disease
[0033] 1. Medicinal Materials
[0034] Astragalus is the dried root of Astragalus membranaceus (Fisch) Bge.var.mongholicus (Bge) Hsiao or Astragalus membranaceus (Fisch) Bge of the Leguminosae family.
[0035] Epimedium is the dried aerial part of Epimedium brevicornum Maxim, Epimedium sagittatum (Sied.EtZucc) Maxim, Epimedium pudescens maxim, Epimedium wushanense TSYing or Epimedium Koreanum Nakai, all of which belong to the Berberidaceae family.
[0036] Rhubarb is the dried roots and rhizomes of Rheum palmatum L., Rheumtanguticum Maxim ex Balf. or medicinal rhubarb Rheum officinale Baill., all of which are plants of the Polygonaceae family.
[0037] 2. Preparation method
[0038] (1) Astragalus
[0039] According to the prescription, 1200 grams of Astragalus membranaceus was taken, and decocted twice with 8 times the amount of water, each time for 1 hour, filtered separately, and the two filtrates were combined, refrigerated for 12 hours, centrifuged, and the supernatant was taken. After ultrafiltration with hollow fiber, a concentrated liquid part enriched in polysaccharides and a permeate part enriched in saponins were obtained. The permeate part was put on an AB-8 resin column, eluted with 95% ethanol, and the ethanol was recovered under reduced pressure to obtain crude polysaccharides and saponins. The crude polysaccharides and saponins were dried and set aside.
[0040] (2) Epimedium and Rhubarb
[0041] According to the prescription, take 1200 grams of epimedium and 600 grams of rhubarb, use 10 times the amount of 70% ethanol to reflux and extract twice, each time for 1 hour, combine the extracts, filter, and concentrate the filtrate under reduced pressure to a thick paste, dilute it 3 to 4 times with distilled water, let it stand for 2 hours, filter, and obtain the crude extracts of icariin and rhubarb anthraquinone, dry them, and set aside.
[0042] (3) According to the prescription, 1200 g of Epimedium was extracted with 6 times 100% methanol by reflux for 2 times, each time for 45 minutes, the extracts were combined, filtered, and the filtrate was concentrated under reduced pressure to a thick paste, diluted 3 to 4 times with distilled water, allowed to stand for 2 hours, filtered, and a crude quercetin extract was obtained, which was dried and set aside.
[0043] Astragalus polysaccharide, astragaloside IV, icariin, quercetin and rhubarb anthraquinone crude extracts were combined and concentrated in a mass ratio of 1.5:1.5:1.0:1.0:1.6, and dextrin was added to prepare granules.
[0044] 3. Quality Standards
[0045] 3.1 Content determination
[0046] (1) Astragalus polysaccharide
[0047] Phenol-sulfuric acid colorimetry
[0048] With glucose as the standard, standard solutions of different concentrations were prepared; 10 grams of the effective part composition of the traditional Chinese medicine was accurately weighed and dissolved in distilled water, and precipitated with 80% ethanol to remove impurities; 5% phenol solution and concentrated sulfuric acid were added to the standard solution and the sample solution respectively, and the mixture was heated in a boiling water bath for 15 minutes after being shaken, and then cooled to room temperature, and the absorbance was measured at a wavelength of 490 nm, and a standard curve was drawn to calculate the content of astragalus polysaccharide in the sample.
[0049] (2) Astragaloside IV
[0050] Thin layer chromatography
[0051] Preparation of reference solution: Accurately weigh astragaloside IV standard and prepare a solution containing 1.04 mg per ml in methanol.
[0052] Preparation of the test solution: take 10 grams of the effective part of the Chinese medicine, add 10 ml of ether and shake, discard the ether solution, add chloroform-n-butanol (2:1) to the drug solution and shake it for 3 times, 15 ml each time, combine the extracts, evaporate to dryness, add 10 ml of water to the residue to dissolve it, add chloroform-n-butanol (2:1) to shake it for 3 times, 15 ml each time, combine the extracts, evaporate to dryness, add 2 ml of methanol to dissolve the residue to obtain the test solution.
[0053] Accurately pipette 1ul and 10ul of the reference solution and 10ul and 10ul of the test solution, respectively, onto a 20×20cm silica gel G thin layer plate; in the same way, accurately pipette 1ul and 10ul of the reference solution and 10ul and 10ul of the test solution 6, 7, 8, 9, respectively, onto the second plate, respectively, using chloroform-methanol-water (65:35:10) placed overnight below 10°C (and adding 2-3 drops of formic acid) as the developing agent, develop, take out, dry, spray with 10% sulfuric acid ethanol solution, bake at 105°C for about 7 minutes until clear purple-red spots appear, take out, cover with a glass plate, seal all around with tape, and scan at λs=520nm. According to the scanning area values of the standard and sample, calculate the content of astragaloside IV by the external standard two-point method.
[0054] (3) Icariin
[0055] High performance liquid chromatography
[0056] Preparation of reference solution: accurately weigh 2.88 mg of icariin standard, place in a 25 ml volumetric flask, add 15 ml of methanol, sonicate to completely dissolve, bring to room temperature, dilute to scale with methanol, shake well to obtain a solution containing 23.04 ug of icariin per 1 ml.
[0057] Preparation of test solution: Take 10g of effective part of Chinese medicine, put it in a ground conical bottle, add 20ml of water, and extract by ultrasonic for 30 minutes. Filter, wash with chloroform 3 times, discard the chloroform layer, saturate the filtrate with water, extract with n-butanol 3 times, 15ml each time, combine the n-butanol solution, evaporate to dryness on a water bath, dissolve the residue with methanol, and make up to 25ml.
[0058] Accurately pipette 10ul of the reference solution and the test solution respectively, and inject them into the liquid chromatograph to determine the icariin content.
[0059] (4) Rhubarb Anthraquinone
[0060] UV spectrophotometry
[0061] Preparation of reference solution: Accurately weigh 1 mg of 1,8-dihydroxyanthraquinone standard, place it in a 10 ml volumetric flask, add ether to the scale, shake well, and obtain the reference solution.
[0062] Preparation of the test solution: take 10 grams of the effective part of the Chinese medicine composition, add 1g of diatomaceous earth, mix well, transfer all of it to a stoppered conical flask, accurately add 25ml of methanol, weigh, place at room temperature for 12 hours, and shake from time to time to make up for the lost amount of methanol, filter, discard the initial filtrate, remove an appropriate amount of the subsequent filtrate, place it in a 20ml stoppered test tube, evaporate the methanol, add 1ml of water, 1ml of 30% hydrogen peroxide, and 0.2ml of concentrated sulfuric acid to the residue, heat it in a water bath for 30 minutes, immediately cool it with running water, add ether to extract until the ether layer is colorless, combine the ether liquid, wash with water until neutral, evaporate the ether liquid, add an appropriate amount of 0.5% magnesium acetate solution to the residue and place it in a volumetric flask, evaporate the ether, add 0.5% magnesium acetate solution to the scale, and determine the anthraquinone content of rhubarb in the visible light region of 498nm.
[0063] (5) Quercetin
[0064] High performance liquid chromatography
[0065] Preparation of reference solution: accurately weigh the quercetin standard, place it in a 25 ml volumetric flask, add 15 ml of methanol, sonicate to completely dissolve it, bring it to room temperature, add methanol to dilute to the scale, and shake well.
[0066] Preparation of the test solution: Take 10 grams of the effective part of the Chinese medicine, put it in a ground-mouth conical bottle, add 20 ml of water, and ultrasonically extract for 30 minutes. Filter, wash with chloroform 3 times, discard the chloroform layer, saturate the filtrate with water, extract 3 times with n-butanol, 15 ml each time, combine the n-butanol solution, evaporate to dryness on a water bath, dissolve the residue with methanol, and make it 25 ml. Accurately pipette 10ul of the reference solution and the test solution respectively, and inject them into the liquid chromatograph to determine the quercetin content.
[0067] 3.2 Results
[0068] Thin layer chromatography determined that every 10 grams of the effective part of the Chinese medicine composition (containing about 10 grams of the compound raw medicine) contained no less than 2.5 mg of astragalus polysaccharide;
[0069] Thin layer chromatography determined that every 10 grams of the effective part of the Chinese medicine composition (containing about 10 grams of the compound raw medicine) contained no less than 2.5 mg of astragaloside IV;
[0070] High performance liquid chromatography determined that every 10 grams of the effective part of the Chinese medicine composition (containing about 10 grams of the compound crude drug) contained no less than 1.8 mg of icariin;
[0071] Ultraviolet spectrophotometry determined that every 10 grams of the effective part of the Chinese medicine composition (containing about 10 grams of the compound crude drug) contained no less than 2.8 mg of 1,8-dihydroxyanthraquinone;
[0072] High performance liquid chromatography determined that every 10 grams of the effective part composition of traditional Chinese medicine (containing approximately 10 grams of compound crude drug) contained no less than 1.8 mg of quercetin.
[0073] Example 2: Experiment on the effect of the effective fraction composition of traditional Chinese medicine on improving renal fibrosis in rat residual kidney model
[0074] 1. Materials
[0075] 1.1 Experimental animals
[0076] Male Wistar rats, weighing 140-180 g, were provided by the Experimental Animal Center of Hubei Academy of Medical Sciences; certificate number, Yidongzi No. 19-073.
[0077] The experimental animals were kept in stainless steel cages. The feed was complete pure mouse pellet feed provided by the feed processing plant of the Experimental Animal Center of Hubei Academy of Medical Sciences. The drinking water was clean tap water.
[0078] The laboratory temperature is 19-29℃, and the relative humidity is 40-80%; the animal environment facility certificate number of Class II animal laboratory is Yidongzi No. 19-069.
[0079] 1.2 Main drugs and reagents
[0080] 1.2.1 Test Drugs
[0081] The effective part composition of traditional Chinese medicine prepared in the example contains 10 grams of compound crude drug per 10 grams. Before the experiment, the product was extracted and diluted into different concentrations of 20%, 40% and 80% of compound crude drug per milliliter, and placed in a 4°C refrigerator for use.
[0082] 1.2.2 Positive control drug
[0083] The positive control drug was provided by the Pharmacy Department of Hubei Provincial Hospital of Traditional Chinese Medicine and is a traditional Chinese medicine that has been used to treat kidney disease.
[0084] 1.2.3 Other drugs and reagents
[0085] Penicillin, a product of North China Pharmaceutical Co., Ltd.; thrombin and gelatin sponge, products of Wuhan Biochemical Pharmaceutical Factory;
[0086] 2. Experimental Methods
[0087] 2.1 Modeling method
[0088] The CRF rat model was established by subtotal nephrectomy. The day before the operation, the rats were depilated and skin prepared on their abdomens. 0.5% sodium pentobarbital 10ml.kg-1 was injected intraperitoneally for the operation. The anesthetized rats were fixed in a supine position on a homemade rat operating table. The skin was routinely disinfected and a towel was laid. The midline of the abdomen was made for surgical incision. The abdominal cavity was opened to expose the left kidney. The fat capsule was peeled off. The renal pedicle was clamped with an artery clamp. The upper and lower poles and the lateral renal tissue were quickly removed. After the excision, gelatin sponge was used to compress and stop bleeding, and the artery clamp was immediately released. If there was bleeding from the incision, thrombin was added. After observing that there was no bleeding from the residual renal tissue, it was returned to the abdominal cavity. The right kidney was then exposed, the renal pedicle was ligated to remove the right kidney, the abdominal cavity was closed, and sutured layer by layer, and then bandaged and fixed with gauze, bandages, and adhesive tape. Penicillin was injected after surgery to prevent infection. The model was successful for about 12 weeks. The sham operation method was the same as the surgical modeling method except that the abdominal cavity was opened without subtotal nephrectomy.
[0089] 2.2 Animal grouping
[0090] One hundred Wistar rats were randomly divided into a normal control group (normal group n=10), a sham operation control group (sham operation group n=15), a model group (model n=15), a low-dose group of the effective part of Chinese medicine composition 2g / kg group (n=15), a medium-dose group of the effective part of Chinese medicine composition 4g / kg group (n=15), a high-dose group of the effective part of Chinese medicine composition 8g / kg group (n=15) and a treatment control group (positive control drug) (n=15).
[0091] 2.3 Dosage
[0092] Twelve weeks after surgical modeling, rats in the normal control group, sham operation group and model group were gavaged with 10 ml / kg of distilled water; rats in the 2g / kg, 4g / kg and 8g / kg groups of the effective part composition of Chinese medicine were gavaged with 10 ml / kg of the effective part composition of Chinese medicine solution of 20%, 40% and 80% respectively; rats in the control group were gavaged with 10 ml / kg of 40% positive control drug, once a day, for 2 consecutive months.
[0093] 2.4 Observation indicators
[0094] 2.4.1 General condition, mental state, activity, fur color, weight gain and survival rate of rats.
[0095] 2.4.2 Histopathology of remnant kidney
[0096] The residual renal tissue was routinely dehydrated with alcohol, embedded in paraffin, and 3 μm thick tissue sections were made.
[0097] HE and Masson staining were used to observe the pathological changes of glomerular sclerosis in the rat kidneys under light microscope.
[0098] 2.4.3Col-IV immunohistochemistry
[0099] Staining was performed according to the instructions of the kit. Paraffin-embedded blocks of residual renal tissue with a thickness of 3 μm were sliced and dewaxed to water in a conventional manner. Freshly prepared distilled water was used to wash 3 times, and the compound digestion solution was added for 10 minutes, and then washed 3 times with distilled water. Normal goat serum blocking solution was added, and after 20 minutes at room temperature, the excess liquid was shaken off, and a 1:100 primary antibody (mouse anti-human and rat type IV collagen) was added, and the reaction time was controlled under the microscope for 120 minutes, and then washed with 0.1 M PBS for 2 minutes × 3 times. Biotinylated goat anti-mouse IgG was added, and the reaction time was controlled under the microscope for 120 minutes, and then washed with 0.1 M PBS for 2 minutes × 3 times. Reagent SABC was added, and the reaction time was controlled under the microscope for 20 minutes, and then washed with 0.1 M PBS for 5 minutes × 4 times. DAB color development [using the DAB color development kit, take 1 ml of distilled water, add 1 drop of each of the A, B, and C reagents in the kit, mix well, and add to the slice. Color development was performed at room temperature, and the reaction time was controlled under the microscope (usually 30 minutes), and then washed with distilled water]. Hematoxylin was used for light counterstaining. Dehydrate, clear, and mount.
[0100] 2.4.4 PCNA immunohistochemistry
[0101] Staining was performed according to the instructions of the kit. The 3um thick paraffin-embedded block of residual renal tissue was dewaxed to water. Washed with freshly prepared distilled water for 2 minutes × 3 times. The slices were immersed in 0.01M citrate buffer, pH 6.0, heated in a microwave oven until boiling and then turned off, and repeated for 10 minutes at intervals, and repeated 3 times to repair the antigen. After cooling, the blocking solution was added dropwise, and the excess liquid was shaken off after 10 minutes at room temperature. Mouse monoclonal anti-proliferating cell nuclear antigen PCNA was added dropwise, 20℃, 120 minutes, and 0.1MPBS was washed for 2 minutes × 3 times. Biotinylated goat anti-mouse IgG was added dropwise, 20℃, 20 minutes, and 0.1MPBS was washed for 2 minutes × 3 times. Reagent SABC was added dropwise, 20℃, 20 minutes, and 0.1MPBS was washed for 5 minutes × 4 times. DAB color development (using the DAB color development kit, take 1ml of distilled water, add 1 drop of each of the A, B, and C reagents in the kit, mix well, and add to the slices. Color development at room temperature, and control the reaction time under the microscope. Wash with distilled water). Lightly counterstained with hematoxylin, dehydrated, transparent, mounted, and observed under a microscope.
[0102] 3. Experimental results
[0103] The residual kidney (RK) model was established by subtotal nephrectomy. After 12 weeks of modeling, pathological changes showed that the model group had massive proliferation of glomerular cells, compensatory hypertrophy of glomeruli, dilation or occlusion of capillaries, and glomerular adhesion; mesangial cell proliferation, widening of mesangial matrix, and dilation of renal tubular lumen (see Appendix). Figure 1 ); glomerular sclerosis, interstitial fibrosis (see Appendix Figure 2 ), which is consistent with the pathological changes of human chronic kidney disease.
[0104] The results showed that compared with the model group, the medium and high dose groups of the effective parts of Chinese medicine reduced glomerular hypertrophy and improved mesangial hyperplasia; the high dose of the effective parts of Chinese medicine was better than the positive control drug group, i.e. the treatment control group (see Appendix Figure 1 );
[0105] Compared with the model group, the medium and high dose groups of the effective part of Chinese medicine composition significantly alleviated glomerular sclerosis and improved interstitial fibrosis. The high dose of the effective part of Chinese medicine composition was superior to the treatment control group (see Appendix Figure 2 );
[0106] Compared with the model group, the expression of Col-IV in the medium and high dose groups of the effective part of the Chinese medicine composition was significantly reduced, and the expression of Col-IV in the high dose group of the effective part of the Chinese medicine composition was significantly reduced compared with the treatment control group (see Appendix Figure 3 );
[0107] The total number of glomerular cells and PCNA-positive cells in the medium and high dose groups of the effective part of Chinese medicine were significantly lower than those in the model group; in terms of reducing the total number of glomerular cells, the high dose group of the effective part of Chinese medicine was significantly better than the treatment control group (see Appendix Figure 4 ).
[0108] The above experiments show that the effective fraction composition of traditional Chinese medicine can reduce the pathological damage and fibrosis of residual renal tissue by inhibiting the proliferation of PCNA-positive cells and total glomerular cells in the kidneys of RK rats and reducing the deposition of extracellular matrix (ECM).
[0109] Example 3: Acute toxicity test of effective fraction composition of traditional Chinese medicine
[0110] Acute toxicity test showed that the MTD of the product was 186g·Kg-1, which was about 360 times of the clinical dosage, indicating that the oral administration of the product had a wide safety range. The highest concentration (4.65g / ml) and the largest volume (40ml / kg) of the effective part of the Chinese medicine composition were gavaged to mice once a day for 7 consecutive days, and there was no death in the mice and no obvious toxic reaction was observed.
[0111] Example 4: Clinical study on the treatment of chronic kidney disease patients with a combination of effective parts of traditional Chinese medicine
[0112] 1. General Information
[0113] A total of 106 cases were observed in this study, all of whom were from outpatients and inpatients of the Nephrology Department of the Affiliated Hospital of Hubei University of Chinese Medicine.
[0114] 2. Treatment Methods
[0115] The granules of the effective part composition of traditional Chinese medicine were provided by the Traditional Chinese Medicine Preparation Room of the Affiliated Hospital of Hubei University of Chinese Medicine (Batch No.: 98000405), 10 g each time, 3 times a day, taken with warm water after meals, for a course of 6 months.
[0116] All patients adopted a high-quality low-protein diet and received symptomatic treatments such as diuresis, blood pressure control, correction of acidosis, correction of anemia, and calcium supplementation according to their condition. Antibiotics were used for those with concurrent infections.
[0117] 3. Observation indicators and methods
[0118] 3.1 TCM observation indicators Observe the clinical symptoms and physical signs of patients before and after treatment, and establish a scoring table. (1) Fatigue: Occasional fatigue, intolerance to labor, can persist in light physical labor (1 point); general activities, intermittent, barely support daily activities (2 points); continuous during rest, unable to persist in daily activities (3 points). (2) Weak waist and knees: Waist and knees are sore in the morning, which can be stopped by beating (1 point); continuous waist pain, knees are weak, and lower limbs are heavy (2 points); unbearable waist pain, knees are weak and unwilling to walk (3 points). (3) Fear of cold and cold limbs: Hands and feet are sometimes afraid of cold, which does not affect clothing, and occurs when there is wind (1 point); often afraid of cold limbs, more obvious than ordinary people, and occurs at night (2 points); the whole body is obviously afraid of cold, and the clothes are one season worse than ordinary people (3 points). (4) Dizziness: Mild dizziness, occurs occasionally, and does not affect activities and work (1 point); severe dizziness, occurs during activities, but can be relieved at rest (2 points); feeling like falling down when walking, which does not improve throughout the day and affects activities and work (3 points). (5) Poor appetite: loss of appetite, and food intake is reduced by no more than 1 / 4 (1 point); loss of appetite, loss of appetite, and food intake is reduced by 1 / 4-1 / 2 (2 points); very poor appetite, no feeling of hunger, and food intake is reduced by more than 1 / 2 (3 points). (6) Nausea: 1-2 times a day (1 point); 3-4 times a day (2 points); frequent nausea, more than 4 times a day (3 points). (7) Vomiting: 1-2 times a day (1 point); 3-4 times a day (2 points); frequent vomiting, more than 4 times a day (3 points). (8) Abdominal distension: Slight abdominal distension, tolerable, does not affect diet (1 point); abdominal distension, relieved by fasting, reduced diet (2 points); abdominal distension, not relieved all day, unbearable (3 points). (9) Defecation frequency: Unformed stool, once a day, or dry stool, once a day (1 point); Unformed stool, twice a day, or constipation, once every two days (2 points); Unformed stool, 3 times a day, or constipation, once every few days (3 points). (10) Frequent urination at night: The amount of nocturnal urine is mostly white, twice a night (1 point); The amount of nocturnal urine is mostly white, 3-4 times a night (2 points); The amount of nocturnal urine is mostly white, more than 5 times a night (3 points); (11) Edema: Eyelid edema in the morning (1 point); Eyelid and lower limb edema (2 points); Systemic edema (3 points). Fill out the clinical observation form regularly.
[0119] 3.2 Western medicine observation indicators
[0120] Serum creatinine (SCr), blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), serum albumin (ALB), and 24-hour urine protein quantification.
[0121] 4. Criteria for determining efficacy
[0122] 4.1 TCM efficacy criteria Significantly effective: Compared with before treatment, the symptom score decreased by 70%-94%. Effective: Compared with before treatment, the symptom score decreased by 30%-69%. Ineffective: Compared with before treatment, the symptom score decreased by <29%.
[0123] 4.2 Western medicine efficacy standards: Significantly effective: symptoms and signs basically disappear, 24h urine protein quantitative continues to decrease by ≥50% compared with the baseline value; or eGFR is maintained at the baseline value (fluctuation ≤5%). Effective: compared with the baseline value, 24h urine protein quantitative decreases by 25%-50%; or eGFR decreases by 5%-20%. Ineffective: does not meet the above efficacy standards.
[0124] 5. Statistical methods
[0125] All data were processed using Excel spreadsheets and SPSS 17.0 statistical software. Count data were expressed as number of cases and percentages, and measurement data were expressed as Paired t test or rank sum test was used for comparison before and after treatment. P < 0.05 was considered statistically significant.
[0126] 6. Results
[0127] 6.1 Comparison of TCM symptom scores before and after treatment, see Table 1.
[0128] The results showed that compared with before treatment, the TCM symptom score was significantly reduced after 6 months of treatment (P < 0.01), indicating that the combination of effective parts of traditional Chinese medicine can better improve the patient's TCM symptom level.
[0129] Table 1 Comparison of TCM symptom scores
[0130]
[0131] Note: Compared with before treatment (0 month), *P<0.01.
[0132] 6.2 Comparison of 24-hour urine protein quantification and ALB before and after treatment is shown in Table 2.
[0133] The results showed that compared with before treatment, there were significant statistical differences in 24-hour urine protein quantification and ALB values after 6 months of treatment (P < 0.01), indicating that the composition of the effective parts of traditional Chinese medicine can reduce the patient's proteinuria content and improve the serum albumin level.
[0134] Table 2 Comparison of 24-hour urine protein and ALB
[0135]
[0136] Note: Compared with before treatment (0 month), *P<0.01; #P>0.05.
[0137] 6.3 Comparison of renal function indicators before and after treatment, see Table 3.
[0138] The results showed that compared with before treatment, there was no significant statistical difference in the various renal function indicators after 6 months of treatment (P>0.05), indicating that the composition of the effective parts of traditional Chinese medicine can maintain the levels of various renal function indicators.
[0139] Table 3 Comparison of renal function indicators
[0140]
[0141] Note: Compared with before treatment (0 month), ﹡P>0.05.
[0142] 6.4 The comparison results of the effectiveness of traditional Chinese medicine and western medicine showed that the total effective rate of treatment with the combination of effective parts of traditional Chinese medicine was 81%, and the total effective rate of western medicine treatment was 49%, see Table 4.
[0143] Table 4 Effects of Chinese and Western medicine (%)
[0144] Significant effect efficient invalid Total Effectiveness Therapeutic Effects of Traditional Chinese Medicine 49(46%) 37(35%) 20(19%) 86(81%) Western medicine efficacy 31(29%) 21(20%) 54(60%) 52(49%)
[0145] 7. Conclusion
[0146] 7.1 Effect of the combination of effective parts of traditional Chinese medicine on proteinuria
[0147] Proteinuria is an important factor that promotes the development of renal failure. Studies have shown that urinary protein has potential nephrotoxicity, so controlling proteinuria is of great significance to patients. The results of this study showed that the quantitative urine protein of the effective part of traditional Chinese medicine composition was significantly reduced after treatment compared with that before treatment 24 hours later (P < 0.01). This indicates that the preparation can reduce the urine protein content of CRF patients, thereby reducing the further damage of proteinuria to the kidneys.
[0148] 7.2 Effect of the combination of effective parts of traditional Chinese medicine on serum ALB
[0149] Due to the decline in glomerular filtration rate (GFR), protein metabolism in the body is unbalanced, decomposition increases and intake is insufficient, resulting in increased blood BUN, decreased ALb, poor nutritional status, affecting the patient's quality of life, and further aggravating kidney damage. The results of this study showed that ALB increased significantly after treatment with the effective part of traditional Chinese medicine composition, indicating that the effective part of traditional Chinese medicine composition can improve clinical symptoms and improve the quality of life of patients by improving protein metabolism and increasing serum albumin.
[0150] 7.3 Effects of the combination of effective parts of traditional Chinese medicine on renal function indicators such as BUN, Scr, and eGFR
[0151] Clinical studies have shown that although the combination of effective parts of traditional Chinese medicine cannot significantly reduce patients' renal function indicators, it can maintain them at a certain level and prevent them from further deteriorating.
[0152] 7.4 Effect of the combination of effective parts of traditional Chinese medicine on the efficacy of traditional Chinese and Western medicine
[0153] Through this study, the effective rates of the composition of effective parts of traditional Chinese medicine in traditional Chinese and Western medicine were 81% and 49% respectively, especially in improving clinical symptoms, it has great advantages and is an effective traditional Chinese medicine formula for the treatment of chronic kidney disease.
[0154] In summary, the present invention provides a composition of effective parts of traditional Chinese medicine for treating chronic kidney disease and a preparation method thereof, extracts effective ingredients for treating chronic kidney disease from traditional Chinese medicine, and studies their optimal weight ratio, thereby solving the problem that the prior art is unclear about the mechanism of action of traditional Chinese medicine on chronic kidney disease and lacks effective traditional Chinese medicine prescriptions for treating chronic kidney disease.
[0155] Finally, it should be noted that the above embodiments are only used to illustrate the present invention and are not intended to limit the protection scope of the present invention. In addition, after reading the technical content of the present invention, those skilled in the art may make various changes, modifications or variations to the present invention, and all of these equivalent forms also fall within the protection scope defined by the present application.
Claims
1. A composition of effective parts of traditional Chinese medicine for treating chronic kidney disease, It is characterized in that The ingredients of the effective part composition of traditional Chinese medicine include astragalus polysaccharide, astragalus saponin, icariin, quercetin and crude extract of rhubarb anthraquinone. In the effective part composition of traditional Chinese medicine, the mass ratio of the astragalus polysaccharide, astragalus saponin, icariin, quercetin and crude extract of rhubarb anthraquinone is: 1-3 parts of the crude extract of astragalus polysaccharide, 1-3 parts of the crude extract of astragalus saponin, 1-2 parts of the crude extract of icariin, 1-2 parts of the crude extract of quercetin and 1-3.2 parts of the crude extract of rhubarb anthraquinone.
2. A composition of effective parts of traditional Chinese medicine for treating chronic kidney disease according to claim 1, It is characterized in that The preparation method of the effective part composition of traditional Chinese medicine comprises the following steps: S1, take 1 portion of Astragalus, add 8 times the amount of water and boil twice, each time for 1 hour, filter separately, combine the two filtrates, refrigerate for 12 hours, centrifuge, take the supernatant, and use hollow fiber ultrafiltration to obtain a concentrated liquid part enriched in polysaccharides and a permeate part enriched in saponins, apply the permeate part to an AB-8 resin column, elute with 95% ethanol, recover the ethanol under reduced pressure, and obtain crude polysaccharides and saponins, dry the crude polysaccharides and saponins, and set aside; S2, take 2 parts of epimedium, extract with 10 times the amount of 70% ethanol under reflux twice, each time for 1 hour, combine the extracts, filter, concentrate the filtrate under reduced pressure to a thick paste, dilute it 3 to 4 times with distilled water, let it stand for 2 hours, filter, obtain a crude extract of icariin, dry it, and set aside; S3, taking 2 parts of Epimedium, reflux extracting with 6 times amount of 100% methanol twice, each time for 45 minutes, combining the extracts, filtering, concentrating the filtrate under reduced pressure to a thick paste, diluting it 3 to 4 times with distilled water, standing for 2 hours, filtering, obtaining a crude extract of quercetin, drying it, and setting it aside; S4, take 1 portion of rhubarb, extract twice with 10 times the amount of 70% ethanol under reflux, each time for 1 hour, combine the extracts, filter, and concentrate the filtrate under reduced pressure to a thick paste, dilute it 3 to 4 times with distilled water, let it stand for 2 hours, filter, and obtain a crude anthraquinone extract of rhubarb for standby use; S5, combining and concentrating the astragalus polysaccharide, astragaloside, icariin, quercetin and rhubarb anthraquinone crude extracts obtained in the above steps according to a component mass ratio of 1-3:1-3:1-2:1-2:1-3.2, and adding auxiliary materials to prepare a clinically applicable dosage form.
3. A Chinese medicine effective part composition for treating chronic kidney disease according to claim 2, It is characterized in that The dosage forms include granules, tablets, capsules or liquid preparations.
4. A Chinese medicine effective part composition for treating chronic kidney disease according to claim 3, It is characterized in that The granules are prepared by combining, concentrating and adding dextrin the astragalus polysaccharide, the astragaloside, the icariin, the quercetin and the crude extract of rhubarb anthraquinone in a component mass ratio of 1.5:1.5:1.0:1.0:1.
6.
5. A composition of effective parts of traditional Chinese medicine for treating chronic kidney disease according to claim 1 or 2, It is characterized in that Every 10 grams of the effective part composition of the traditional Chinese medicine contains no less than 2.5 mg of astragaloside IV, no less than 2.5 mg of astragaloside IV, no less than 1.8 mg of icariin, no less than 2.8 mg of 1,8-dihydroxyanthraquinone, and no less than 1.8 mg of quercetin.
6. Use of a composition of effective parts of traditional Chinese medicine for treating chronic kidney disease according to claim 4 or 5 in the preparation of a medicine for treating chronic kidney disease.
Citation Information
Patent Citations
New Chinese medicine for treating early and middle-stage diabetic nephropathy
CN102228521A
Traditional Chinese medicine composition for treatment of chronic renal diseases and chronic renal failure and its preparation method and use
CN103893284A
Uses of icariin or icariside II in prevention and treatment of kidney diseases
CN105079014A
